RAFAEL PHARMACEUTICALS
Rafael Pharmaceuticals is a provider of metabolic oncology therapeutics intended to treat cancer patients. The company's metabolic oncology therapeutics applies unique bio-energetic processes specific to cancer and provide altered cancer metabolism directed therapies and novel, first-in-class drugs and drug delivery technologies, enabling patients to get revolutionized cancer treatment.
RAFAEL PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2000-01-01
Address:
Cranbury, New Jersey, United States
Country:
United States
Website Url:
http://www.rafaelpharma.com
Total Employee:
11+
Status:
Active
Contact:
(609) 409 7050
Email Addresses:
[email protected]
Total Funding:
35.18 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Calimmune
Calimmune is a clinical-stage gene therapy company.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Xenon Pharmaceuticals
Xenon Pharmaceuticals operates as a neurology-focused biopharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Chetrit Ventures
Chetrit Ventures investment in Corporate Round - Rafael Pharmaceuticals
IDT Corporation
IDT Corporation investment in Corporate Round - Rafael Pharmaceuticals
Althea Partners
Althea Partners investment in Series B - Rafael Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-23 | Rafael resets after phase 3 flop, parting ways with 5 execs and reinstating telecom tycoon as CEO |
Official Site Inspections
http://www.rafaelpharma.com
- Host name: 151.101.130.159
- IP address: 151.101.130.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Rafael Pharmaceuticals"
Rafael Pharmaceuticals - Rafael Holdings
It has been known for nearly a century that cancer cells have a unique metabolism compared to normal cells. Only recently, however, has there been a broad and significant renewal of …See details»
Rafael Pharmaceuticals - Crunchbase Company Profile …
Contact Email [email protected] Phone Number (609) 409 7050 Rafael Pharmaceuticals is a provider of metabolic oncology therapeutics intended to treat cancer patients.See details»
Executive Management Team | Cornerstone …
John Goldberg, MD has served as Chief Executive Officer of Cornerstone Pharmaceuticals since March 26, 2024 and as Chief Medical Officer of Rafael Holdings since November 20, 2023. Dr. Goldberg is a seasoned biotech …See details»
Rafael Holdings Announces Strategic Merger with …
Jun 21, 2021 · NEWARK, N.J. and CRANBURY, N.J., June 21, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL) announced that it has entered into a merger agreement with Rafael Pharmaceuticals, Inc., a...See details»
Rafael Holdings Appoints Three Highly Experienced …
NEWARK, N.J., June 14, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical company focused on developing novel cancer metabolism therapeutics, today …See details»
President and CEO of Rafael Pharmaceuticals, Sanjeev
Aug 26, 2021 · Rafael Pharmaceuticals is a leader in the growing field of cancer metabolism. The company is developing a new, first-in-class category of metabolic oncology therapeutics that …See details»
President and CEO of Rafael Pharmaceuticals, Sanjeev Luther, to …
CRANBURY, N.J., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, …See details»
Rafael Holdings Expands Leadership Team with Three Highly …
Aug 17, 2021 · The Company plans continues to discover and advance its internal cancer metabolism research programs and expects its Dual-SHMT Inhibitor to enter Phase 1 in late …See details»
Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan …
CRANBURY, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, …See details»
Rafael Holdings Expands Leadership Team with Three Highly …
NEWARK, N.J., Aug. 17, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical company focused on developing novel cancer metabolism therapeutics, today …See details»
Rafael Pharmaceuticals Announces First Patient Enrolled in …
Nov 11, 2021 · On June 21, 2021, we announced that we have entered into a merger agreement with Rafael Holdings, Inc. to create a publicly traded late-stage clinical oncology company …See details»
Rafael Pharmaceuticals Receives Approvals to Open Trial
Apr 23, 2020 · Rafael Pharmaceuticals is a leader in the growing field of cancer metabolism. The company is developing a new, first-in-class category of metabolic oncology therapeutics that …See details»
Rafael Pharmaceuticals to Present New Pancreatic Cancer and
May 26, 2021 · Rafael Pharmaceuticals is a leader in the growing field of cancer metabolism. The company is developing a new, first-in-class category of metabolic oncology therapeutics that …See details»
Rafael Holdings Announces Strategic Merger with Rafael ... - Nasdaq
Jun 21, 2021 · NEWARK, N.J. and CRANBURY, N.J., June 21, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL) announced that it has entered into a merger agreement with …See details»
Rafael Holdings Expands Leadership Team with Three Highly …
Aug 17, 2021 · Rafael Pharmaceuticals is a clinical-stage oncology company focused on selectively targeting cancer metabolic pathways while simultaneously harnessing the immune …See details»
Rafael Pharmaceuticals Provides Update on Pivotal Phase 3 Clinical ...
Oct 29, 2021 · Social Contribution Activities; Efforts for the Advancement of Medicine and Pharmacy; Efforts for Supporting Health of Patients and Their FamiliesSee details»
Rafael Pharmaceuticals Announces Successful Completion of Dose ...
Jan 6, 2022 · On June 21, 2021, we announced that we have entered into a merger agreement with Rafael Holdings, Inc. to create a publicly traded late-stage clinical oncology company …See details»
Rafael Pharmaceuticals Announces the Successful Completion
Aug 25, 2021 · On June 21, 2021, we announced that we have entered into a merger agreement with Rafael Holdings, Inc., to create a publicly traded late-stage clinical oncology company …See details»
Rafael Holdings Announces Strategic Merger with Rafael
Jun 21, 2021 · NEWARK, N.J. and CRANBURY, N.J., June 21, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL) announced that it has entered into a merger agreement with …See details»
Rafael Pharmaceuticals Provides Update on Pivotal Phase 3
Oct 28, 2021 · On June 21, 2021, we announced that we have entered into a merger agreement with Rafael Holdings, Inc. to create a publicly traded late-stage clinical oncology company …See details»